Navigation Links
Neuland Labs Reports Second Quarter Fiscal Year 2013 Financial Results
Date:11/9/2012

HYDERABAD, India, Nov. 9, 2012 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE: NEULANDLAB; BOM: 524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract research and manufacturing services to customers located in 85 countries, today announced financial results for the second quarter of fiscal year (FY) 2013, ended September 30, 2012.

Revenues for the second quarter of FY 2013 were $21.37 million (1.18 billion INR*), compared to revenues in the second quarter of FY 2012 of $22.32 million (1.23 billion INR), a decrease of 4.3%. Neuland reported EBITDA of $2.16 million (119.45 million INR) in the second quarter of FY 2013, compared to EBITDA of $2.02 million (111.84 million INR) in the comparable period in FY 2012, an increase of 6.8%. 

The company reported after-tax profits in the second quarter of FY 2013 of $0.56 million (30.85 million INR), compared to a loss of $0.23 million, (negative12.58 million INR), in the second quarter of FY 2012.  

"In the second quarter of FY 2013 we continued to deliver on our goal of achieving consistently profitable operations," said Dr. D.R. Rao, Chairman and Managing Director of Neuland Labs.  "This is our fourth consecutive quarter of profitability, and the eighth consecutive quarter that we have reported revenues greater than one billion Indian rupees."

"We believe that our investments in marketing and business development are building the foundation for both near and long-term revenue growth," noted Sucheth R. Davuluri, Chief Executive Officer of Neuland Labs.  "Our revenue growth for the first half of fiscal year 2013 is up compared to the first six months of last year, and our enhanced efforts to manage costs resulted in an increase in profits despite the modest sales dip in the second quarter.  While the increase in sales in the first half was partly the result of the strengthening of the US dollar against the rupee, the increased margins we are achieving are primarily due to our success in making our key API products more profitable by implementing ongoing process improvements."

For a complete set of Neuland's FY 2013 and FY 2012 financial data, visit http://neulandlabs.com/about/financials.html.Neuland Laboratories is listed on India's National Stock Exchange under the symbol NEULANDLAB and on the Bombay Stock Exchange under code 524558 and the symbol Neuland.EO.* = Indian rupees

About Neuland Labs
For over 25 years Neuland Labs has been at the forefront of supporting drug development through its consulting services and its cGMP contract and API manufacturing, working with customers in over 100 countries. The company is committed to research, supporting a state-of-the-art R&D operation.  Neuland Labs scientists have developed more than 300 processes from bench scale to commercial production, developed over 60 APIs, and filed more than 40 US drug master files, 10 EU CEPs and a total of more than 400 DMFs worldwide. Its manufacturing facilities are inspected and approved by the FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the FDA, TGA, EDQM, German Health Authority, ISO 14001, ISO 27001 and OHSAS 18001. For more information, visit www.NeulandLabs.com.Contacts:Neuland Laboratories Ltd. US MediaNS Viswanathan BLL Partners/Brandwidth SolutionsVice President- Finance Barbara Lindheim+91 40 30211600+1 212 584-2276nsviswanathan@neulandlabs.com blindheim@bllbiopartners.com


'/>"/>
SOURCE Neuland Laboratories Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuland Labs Reports First Quarter Fiscal Year 2013 Financial Results
2. Neuland Labs Reports Financial Results For Fiscal Year 2012
3. GenVec Reports Third Quarter 2012 Financial Results
4. HeartWare Reports Third Quarter 2012 Results
5. Nephros Reports Third Quarter 2012 Financial Results
6. China Biologic Reports Financial Results for the Third Quarter and First Nine Months of 2012
7. CareFusion Reports Preliminary First Quarter Fiscal 2013 Results
8. Verenium Reports Financial Results For The Third Quarter And Nine Months Ended September 30, 2012
9. NxStage Reports Record Revenue for the Third Quarter of Fiscal 2012
10. Discovery Labs Reports Third Quarter 2012 Financial Results
11. Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... and PUNE, India , January 24, ... by Allied Market Research, titled, "Acidity Regulators Market - ... market for acidity regulators was valued at $4,456 million in 2015, ... a CAGR of 7.96% from 2016 to 2022. Asia-Pacific ... to maintain its lead, followed by North America ...
(Date:1/24/2017)... SAN FRANCISCO , January 24, 2017 ... reach a value of USD 3.8 billion by 2025, ... Inc. The market growth can be attributed to the ... awareness about early diagnosis of micro calcifications in breast ... Cancer Foundation, CDC, and Breast Cancer Organization are promoting ...
(Date:1/24/2017)... For today, Stock-Callers.com scans the following Biotechnology companies: ... Inc. (NASDAQ: ALDR ), BioDelivery Sciences International Inc. ... EGLT ). These equities are part of the Healthcare ... , 2017, with the NYSE Health Care Index dropping about ... 500 also were down 0.3% as a group. These stocks ...
Breaking Medicine Technology:
(Date:1/24/2017)... Milford, PA (PRWEB) , ... January 24, 2017 ... ... their main product “Lacto-Freedom” was recently accepted as a Registered Trademark by the ... prevent others from using a similar name which could confuse consumers into thinking ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... to the semi-final round of the 2017 Cupid's Cup Entrepreneurship Competition. Chaired by ... 12th year in 2017. The entrepreneurs will showcase their businesses on February 6, ...
(Date:1/24/2017)... ... January 24, 2017 , ... OMI Industries, a worldwide ... a distribution partnership with Byers Scientific & Manufacturing , a leading designer, ... the agreement, OMI Industries formulated a special version of Ecosorb® for Byers Scientific ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... Center ... 21st century leadership, has named Hector M. Chavez, Manager, Employee & Labor Relations at ... center - as its Hispanic Leader of the Month. City of Hope is committed ...
(Date:1/24/2017)... , ... January 24, 2017 , ... The University of ... taken great care to design a program that provides teachers with the specific skills ... This online teaching certificate is ideal for post-baccalaureate students and HigherEducation.com is working to ...
Breaking Medicine News(10 mins):